INVO
Income statement / Annual
Last year (2024), INVO Bioscience, Inc.'s total revenue was $6.53 B,
an increase of 216,150.22% from the previous year.
In 2024, INVO Bioscience, Inc.'s net income was -$9.35 B.
See INVO Bioscience, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$6.53 B |
$3.02 M |
$822.20 K |
$4.16 M |
$1.04 M |
$1.48 M |
$494.38 K |
$282.15 K |
$50.90 K |
$11.69 K |
| Cost of Revenue |
$3.66 B
|
$1.93 M
|
$331.52 K
|
$145.05 K
|
$88.76 K
|
$139.67 K
|
$90.37 K
|
$51.95 K
|
$15.09 K
|
$7.81 K
|
| Gross Profit |
$2.87 B
|
$1.09 M
|
$490.67 K
|
$4.02 M
|
$948.53 K
|
$1.34 M
|
$404.01 K
|
$230.19 K
|
$35.81 K
|
$3.88 K
|
| Gross Profit Ratio |
0.44
|
0.36
|
0.6
|
0.97
|
0.91
|
0.91
|
0.82
|
0.82
|
0.7
|
0.33
|
| Research and Development Expenses |
$489.66 M
|
$165.95 K
|
$544.04 K
|
$216.43 K
|
$398.43 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.08 B
|
$7.49 M
|
$10.57 M
|
$9.02 M
|
$6.07 M
|
$3.13 M
|
$3.04 M
|
$870.61 K
|
$2.15 M
|
$598.95 K
|
| Other Expenses |
$1.43 B
|
$200.89 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$11.00 B
|
$7.85 M
|
$11.12 M
|
$9.23 M
|
$6.46 M
|
$3.13 M
|
$3.04 M
|
$870.61 K
|
$2.15 M
|
$598.95 K
|
| Cost And Expenses |
$14.66 B
|
$9.79 M
|
$11.45 M
|
$9.38 M
|
$6.55 M
|
$3.27 M
|
$3.13 M
|
$922.57 K
|
$2.16 M
|
$606.76 K
|
| Interest Income |
$0.00
|
$0.00
|
$308.00
|
$3.66 K
|
$4.19 K
|
$8.63 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$1.06 B
|
$925.91 K
|
$59.45 K
|
$1.27 M
|
$2.84 M
|
$387.65 K
|
$442.03 K
|
$20.87 K
|
$13.84 K
|
$32.02 K
|
| Depreciation & Amortization |
$919.60 M
|
$200.89 K
|
$306.32 K
|
$166.08 K
|
$34.48 K
|
$25.35 K
|
$5.19 K
|
$2.81 K
|
$1.88 K
|
$5.63 K
|
| EBITDA |
-$9.51 B |
-$6.88 M |
-$10.52 M |
-$5.22 M |
-$5.48 M |
-$1.76 M |
-$2.63 M |
-$678.48 K |
-$2.11 M |
-$4.92 M |
| EBITDA Ratio |
-1.46
|
-2.28
|
-12.8
|
-1.25
|
-5.28
|
-1.19
|
-5.32
|
-2.4
|
-41.42
|
-421.05
|
| Operating Income Ratio |
-1.24
|
-2.24
|
-12.92
|
-1.25
|
-5.32
|
-1.21
|
-5.33
|
-2.27
|
-41.46
|
-50.91
|
| Total Other Income/Expenses Net |
-$993.26 M
|
-$1.24 M
|
-$263.16 K
|
-$1.43 M
|
-$2.83 M
|
-$379.02 K
|
-$442.03 K
|
-$61.74 K
|
-$13.84 K
|
-$4.36 M
|
| Income Before Tax |
-$9.12 B
|
-$8.01 M
|
-$10.89 M
|
-$6.65 M
|
-$8.35 M
|
-$2.17 M
|
-$3.08 M
|
-$702.16 K
|
-$2.12 M
|
-$4.96 M
|
| Income Before Tax Ratio |
-1.4
|
-2.65
|
-13.24
|
-1.6
|
-8.05
|
-1.46
|
-6.22
|
-2.49
|
-41.73
|
-424.27
|
| Income Tax Expense |
-$22.91 M
|
$27.79 K
|
$2.87 K
|
$4.76 K
|
$36.00
|
$433.00
|
$0.00
|
$0.00
|
$0.00
|
$32.02 K
|
| Net Income |
-$9.35 B
|
-$8.03 M
|
-$10.89 M
|
-$6.65 M
|
-$8.35 M
|
-$2.17 M
|
-$3.08 M
|
-$702.16 K
|
-$2.12 M
|
-$4.96 M
|
| Net Income Ratio |
-1.43
|
-2.66
|
-13.25
|
-1.6
|
-8.05
|
-1.46
|
-6.22
|
-2.49
|
-41.73
|
-424.27
|
| EPS |
-3019.48 |
-5.13 |
-17.97 |
-12.52 |
-30.41 |
-8.93 |
-12.76 |
-3.16 |
-9.67 |
-23.15 |
| EPS Diluted |
-3019.48 |
-5.13 |
-17.97 |
-12.52 |
-30.41 |
-8.93 |
-12.76 |
-3.16 |
-9.67 |
-23.15 |
| Weighted Average Shares Out |
$3.10 M
|
$1.57 M
|
$606.13 K
|
$531.62 K
|
$274.49 K
|
$242.74 K
|
$241.08 K
|
$222.08 K
|
$219.68 K
|
$214.20 K
|
| Weighted Average Shares Out Diluted |
$3.10 M
|
$1.57 M
|
$606.13 K
|
$531.62 K
|
$274.49 K
|
$242.74 K
|
$241.08 K
|
$222.08 K
|
$219.68 K
|
$214.20 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
